Trial Profile
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer: a Single-arm, Ahead, Open-label Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Pyrotinib (Primary) ; Carboplatin; Docetaxel; Trastuzumab
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 09 Jun 2023 Primary endpoint (pCR) has been met, as per results published in the Oncology Research and Treatment.
- 09 Jun 2023 Status changed to completed, as per results published in the Oncology Research and Treatment.
- 09 Jun 2023 Results (recruited from Oct 1, 2019, to Jun 1, 2021) assessing the efficacy and safety of pyrotinib plus trastuzumab, docetaxel, and carboplatin in early or locally advanced HER2-positive breast cancer, published in the Oncology Research and Treatment.